NEW YORK, Feb. 4 - Functional proteomics firm Hybrigenics will collaborate with biomarker company Mindsense Biosystems to identify markers and drug targets linked with depression, the two companies said.
Mindsense Biosystems has a portfolio of blood-based biomarkers for depression and wants to use proteomics and functional genomics to develop them. To that end, Hybrigenics will apply its high-throughput proteomics techniques to identify proteins that interact with Mindsense targets, and validate those proteins as targets through cell-based phenotypic assays.
Financial details of the arrangement were not revealed.
Mindsense, based in Rehovot, Israel, was launched in 1998 to develop technology invented at Ben Gurion University. It focuses on developing diagnostics for mental disorders.
Paris-based Hybrigenics provides functional genomics services for a range of biotech firms. Its in-house drug-development efforts include research into infectious diseases, cancer and metabolic disorders.